<DOC>
	<DOCNO>NCT01172028</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Pemetrexed disodium may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose give pemetrexed disodium docetaxel together treat patient advance solid tumor .</brief_summary>
	<brief_title>Pemetrexed Disodium Docetaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum-tolerated dose combination pemetrexed disodium docetaxel administer day 1 day 15 dosing schedule . Secondary - To specifically characterize toxicity profile combination biweekly pemetrexed disodium docetaxel . - To investigate antitumor activity patient advance solid tumor measure RECIST criterion patient measurable disease tumor marker patient non-measurable disease . - To determine recommended phase II dose combination pemetrexed disodium docetaxel biweekly dose schedule . OUTLINE : This dose-escalation study . Patients receive pemetrexed disodium IV 10 minute docetaxel IV day 1 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance recurrent solid tumor Patients docetaxel consider appropriate anticancer therapy ; docetaxel currently approve use patient follow solid tumor : Nonsmall cell lung ( NSCLC ) Breast Prostate Esophageal Head neck Ovarian Gastric Measurable nonmeasurable disease No squamous cell NSCLC Controlled brain metastasis allow Clinically stable sign progression MRI CAT scan ≥ 60 day treatment Patients must asymptomatic steroid requirement PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 12 week WBC ≥ 3,000/mm^3* ANC ≥ 1,500/mm^3* Hemoglobin ≥ 9 g/dL Platelet count ≥ 100,000/mm^3 Total bilirubin normal AST , ALT , alkaline phosphatase ( AP ) must meet one follow criterion : AST ALT ≤ 3** time upper limit normal ( ULN ) AND AP normal AST ALT ≤ 1.5 time ULN AND AP ≤ 2.5 time ULN AST ALT normal AND AP ≤ 5 time ULN Calculated creatinine clearance ≥ 45 mL/min OR GFR measure Tc99mDPTA serum clearance method Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment Able interrupt aspirin NSAIDs pre post twicemonthly drug dose Able take folic acid , vitamin B12 , corticosteroids No uncontrolled serious active infection No preexist peripheral neuropathy &gt; grade 1 No significant cardiac disease ( i.e. , uncontrolled high blood pressure , unstable angina , congestive heart failure within past 6 month , LVEF &lt; normal , myocardial infarction within past year , serious cardiac arrhythmia require medication ) No know severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 NOTE : *No concurrent colonystimulating factor maintain value NOTE : **For patient liver metastasis , AST ALT ≤ 5 time ULN AND AP normal PRIOR CONCURRENT THERAPY : See Disease Characteristics Have receive 01 prior systemic therapy regimen ( prior adjuvant chemotherapy consider prior systemic therapy regimen ) At least 4 week since prior systemic anticancer therapy ( 6 week mitomycin C nitrosoureas ) At least 2 week since prior radiotherapy recover side effect ≤ grade 1 At least 2 week since prior pleurodesis No concurrent radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>stage III basal cell carcinoma lip</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent hypopharyngeal cancer</keyword>
	<keyword>stage III hypopharyngeal cancer</keyword>
	<keyword>stage IV hypopharyngeal cancer</keyword>
	<keyword>recurrent laryngeal cancer</keyword>
	<keyword>stage III laryngeal cancer</keyword>
	<keyword>stage IV laryngeal cancer</keyword>
</DOC>